Medication info
Rosumedi Tablet 10mg (Rosuvastatin Calcium)

Rosumedi Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Telcon RF Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/PPT [(15 tablets/PTP x 2)]
Approval status
Active

MFDS item code 201908417 · Approved 2019.12.14 · Insurance code 625501120

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. Adjust the maintenance dose appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medication to patients with active liver disease. 6. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. A dose of 40 milligrams is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. A dose of 40 milligrams of this medication is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data for doses above 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or more. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Telcon RF Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • High cholesterol
  • hyperlipidemia
  • familial hypercholesterolemia
  • dysbetalipoproteinemia
  • cardiovascular disease risk factors
  • stroke risk
  • myocardial infarction risk
View approved original text

This medication is used as an adjunct for patients with primary hypercholesterolemia and mixed hyperlipidemia who have difficulty controlling their condition with diet and exercise alone. It is also beneficial for patients with homozygous familial hypercholesterolemia in combination with dietary therapy or other lipid-lowering therapies. Additionally, it lowers total cholesterol and LDL cholesterol levels in patients with high cholesterol, effectively delaying the progression of atherosclerosis. It is used as an adjunct to dietary therapy in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia and is also administered as an adjunct treatment for patients with primary dysbetalipoproteinemia. Furthermore, it helps reduce the risk of stroke, myocardial infarction, and vascular revascularization procedures in middle-aged or older patients with high levels of high-sensitivity C-reactive protein, indicating a high risk of cardiovascular disease. Thus, this medication is effective for cholesterol management and cardiovascular disease prevention.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. Adjust the maintenance dose appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medication to patients with active liver disease. 6. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. A dose of 40 milligrams is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. A dose of 40 milligrams of this medication is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data for doses above 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or more. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, patients allergic to this medicine, those with severe liver dysfunction, muscle disorders, severely impaired kidney function, pregnant or breastfeeding women, and those taking certain medications should not use this medication. Additionally, liver function and muscle condition should be regularly monitored while using this medication. Caution is particularly needed for patients who consume large amounts of alcohol or have a history of liver disease, hypothyroidism, and elderly patients. If symptoms of muscle pain or weakness occur, they should immediately inform their physician, and discontinuation of the medication may be necessary. This medication may increase blood sugar levels in some patients, raising the risk of diabetes; therefore, patients at risk for diabetes should have regular blood sugar-related tests. This medication may interact with other drugs, so if other medications are being taken, it is essential to inform the physician or pharmacist. In particular, concomitant use with certain antiviral agents, immunosuppressants, antibiotics, and fibrate drugs may increase the risk of muscle toxicity. Women who are pregnant or planning to become pregnant should not take this medication and should use appropriate contraceptive methods. In the case of overdose, there is no specific antidote, so one should seek appropriate treatment at a hospital immediately and monitor liver function and muscle enzyme levels. Rarely, side effects such as skin rash, itching, headache, dizziness, indigestion, muscle pain, weakness, hematuria, diarrhea, fatigue, numbness, abnormal sensations, chest discomfort, loss of appetite, abdominal distension, syncope, body ache, muscle cramps, gout, erectile dysfunction, memory loss, peripheral neuropathy, cough, thrombocytopenia, hepatitis, increased transaminase levels, eosinophilia, and drug reaction with eosinophilia and systemic symptoms syndrome may occur; thus, it is important to inform healthcare personnel of any unusual symptoms. Lastly, this medication does not significantly affect driving or operating machinery, but caution should be exercised due to the possibility of dizziness.

Side effects

Hypersensitivity reactions, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia with systemic symptom drug reaction syndrome, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, ALT elevation, chest pain, muscle cramps, gout, erectile dysfunction, AST elevation, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, and it is best kept at room temperature between 1 and 30 degrees Celsius. Proper storage will maintain the effectiveness of the medication and prevent deterioration.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/PPT [(15 tablets/PTP x 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.